Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors
June 30 2021 - 8:30AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultra-rare genetic diseases, today
announced the appointment of Corsee Sanders, Ph.D., to the Board of
Directors, effective June 29, 2021. Dr. Sanders, an experienced
veteran of the biopharma industry, will serve as an independent
director.
“Dr. Sanders’ established experience in global clinical
development and especially with new technologies will be
instrumental as we further advance our ongoing clinical trials and
continue to expand our rare disease pipeline of novel therapeutics
for patients who have no other treatment options,” said Emil D.
Kakkis, M.D., Ph.D., Chief Executive Officer and President of
Ultragenyx.
Dr. Sanders most recently served as strategic advisor to the
Chief Medical Officer (CMO) of Celgene, following Celgene’s
acquisition of Juno where she was an Executive Vice President of
Development Operations. She also served as Transition Advisor to
Bristol Myers Squibb (BMS), which acquired Celgene. In those roles,
she ensured the effective integration of Juno’s Chimeric Antigen
Receptor T (CAR-T) Cell Development Organization into the Celgene
and BMS organizations. Prior to that, Dr. Sanders held numerous
leadership positions over the course of 23 years at
Genentech/Roche, including serving as Senior Vice President, Global
Head of Clinical Operations and Industry Collaboration, for six
years.
“The ability to quickly develop effective medicines is
critically important in rare diseases, where patients have few or
no treatment options,” said Dr. Sanders. “I am thrilled to join the
Ultragenyx Board and support the executive team as it works
diligently to make a significant impact on these patient
populations.”
Currently, Dr. Sanders serves as a member of the Board of
Directors of several biotechnology companies including Beigene Ltd.
(NASDAQ: BGNE), Molecular Templates Inc. (NASDAQ: MTEM), Legend
Biotech Corporation (NASDAQ: LEGN), and AltruBio (formerly
AbGenomics) Inc. She is a member of the Board of Trustees and Chair
of the Research Ethics Committee for the Fred Hutchinson Cancer
Research Center, a non-profit cancer research organization in
Seattle. Dr. Sanders graduated magna cum laude from the University
of the Philippines where she earned a B.S. and M.S. in statistics.
She also earned an M.A. and Ph.D. in statistics from the Wharton
Doctoral Program at the University of Pennsylvania.
About Ultragenyx Pharmaceutical Inc.Ultragenyx
is a biopharmaceutical company committed to bringing novel
therapies to patients for the treatment of serious rare and
ultra-rare genetic diseases. The company has built a diverse
portfolio of approved medicines and treatment candidates aimed at
addressing diseases with high unmet medical need and clear biology,
for which there are typically no approved therapies treating the
underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.Investors &
MediaJoshua Higa415-475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2023 to Apr 2024